Hjem
Amani Thomas Moris bilde

Amani Thomas Mori

Forsker, Senior Researcher in Essential NCD project - Tanzania
  • E-postamani.mori@uib.no
  • Besøksadresse
    Alrek helseklynge, blokk D, Årstadveien 17
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). Whether or not to enroll, and stay enrolled? A Tanzanian cross-sectional study on voluntary health insurance. Health Policy OPEN.
  • Vis forfatter(e) (2023). Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa. Nature Communications. 1-10.
  • Vis forfatter(e) (2023). Mandatory health insurance for the informal sector in Tanzania—has it worked anywhere! Frontiers in Health Services.
  • Vis forfatter(e) (2023). Healthcare utilization and catastrophic health expenditure in rural Tanzania: does voluntary health insurance matter? BMC Public Health.
  • Vis forfatter(e) (2023). Estimating the burden of severe malarial anaemia and access to hospital care in East Africa. Nature Communications.
  • Vis forfatter(e) (2023). Cost of image-guided percutaneous nephrostomy among cervical cancer patients at Muhimbili National Hospital in Tanzania. Cost Effectiveness and Resource Allocation. 8 sider.
  • Vis forfatter(e) (2022). Post-discharge morbidity and mortality in children admitted with severe anaemia and other health conditions in malaria-endemic settings in Africa: a systematic review and meta-analysis. The Lancet Child and Adolescent Health. 474-483.
  • Vis forfatter(e) (2022). Health Technology Assessment in Tanzania: Capacity and experience of HTA committee members. Journal of Global Health Economics and Policy.
  • Vis forfatter(e) (2022). Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis. EClinicalMedicine. 1-13.
  • Vis forfatter(e) (2022). Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization. Vaccine. 3278-3285.
  • Vis forfatter(e) (2021). Implementing standard antenatal care interventions: health system cost at primary health facilities in Tanzania. Cost Effectiveness and Resource Allocation. 8 sider.
  • Vis forfatter(e) (2021). Economic consequences of caesarean section delivery: evidence from a household survey in Tanzania. BMC Health Services Research. 1-11.
  • Vis forfatter(e) (2021). Do household perceptions influence enrolment decisions into community-based health insurance schemes in Tanzania? BMC Health Services Research. 11 sider.
  • Vis forfatter(e) (2021). ABC-VEN Analysis of Medicine Expenditure at Mwananyamala Regional Hospital in Tanzania. Modern Economy.
  • Vis forfatter(e) (2020). Vaccine storage and distribution between expanded program on immunization and medical store department in Tanzania: a cost-minimization analysis. Vaccine. 8130-8145.
  • Vis forfatter(e) (2020). Prices of medicines for the management of pain, diabetes and cardiovascular diseases in private pharmacies and the national health insurance in Tanzania. International Journal for Equity in Health. 1-9.
  • Vis forfatter(e) (2019). The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan. BMC Health Services Research.
  • Vis forfatter(e) (2017). Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial. Trials. 1-10.
  • Vis forfatter(e) (2016). Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania. Social Science and Medicine. 208-217.
  • Vis forfatter(e) (2016). Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study. BMC Health Services Research.
  • Vis forfatter(e) (2016). Budget impact analysis of using dihydroartemisinin–piperaquine to treat uncomplicated malaria in children in Tanzania. PharmacoEconomics (Auckland). 303-314.
  • Vis forfatter(e) (2014). The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania. PLOS ONE. 10 sider.
  • Vis forfatter(e) (2014). Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malaria Journal.
  • Vis forfatter(e) (2013). Role of pharmacoeconomics in developing countries. Farmeconomia. Health economics and therapeutic pathways. 3-5.
  • Vis forfatter(e) (2013). Reforms: a quest for efficiency or an opportunity for vested interests'? a case study of pharmaceutical policy reforms in Tanzania. BMC Public Health. 6 sider.
  • Vis forfatter(e) (2012). Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework. Implementation Science. 8 sider.
Faglig foredrag
  • Vis forfatter(e) (2019). Farmasøyter med og uten genser: Hvordan farmasiutdanningene i Bergen og Dar es Salaam blir bedre av et nord-sør samarbeid .
Vitenskapelig foredrag
  • Vis forfatter(e) (2021). Epidemiological impact of PMC.
  • Vis forfatter(e) (2018). Post-discharge risks of morbidity and mortality in children in malaria endemic settings in Africa: A systematic review and meta-analysis - Oral presentation.
  • Vis forfatter(e) (2018). Post-discharge Malaria Chemoprevention for Children Under the Age of 5 years in Africa.
Doktorgradsavhandling
  • Vis forfatter(e) (2015). Pharmacoeconomics and Formulary Decision-Making in Tanzania. Generating Evidence for Antimalarial Drugs.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2020). Patient and health system costs of managing pregnancy and birth-related complications in sub-Saharan Africa: A systematic review. Health Economics Review. 1-15.
  • Vis forfatter(e) (2018). Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: A retrospective review of data from the regulatory authority. BMJ Open. 1-7.
  • Vis forfatter(e) (2012). Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Medical Informatics and Decision Making. 9 sider.

Se fullstendig oversikt over publikasjoner i CRIStin.